Lyka Labs Limited (LYKALABS) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.135x

Based on the latest financial reports, Lyka Labs Limited (LYKALABS) has a cash flow conversion efficiency ratio of 0.135x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Rs136.84 Million ≈ $1.48 Million USD) by net assets (Rs1.01 Billion ≈ $10.96 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Lyka Labs Limited - Cash Flow Conversion Efficiency Trend (2005–2025)

This chart illustrates how Lyka Labs Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Lyka Labs Limited balance sheet liabilities for a breakdown of total debt and financial obligations.

Lyka Labs Limited Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Lyka Labs Limited ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Wästbygg Gruppen AB (publ)
ST:WBGR-B
0.046x
Pioneer Motor Public Company Limited
BK:PIMO
0.043x
Atomos Ltd
AU:AMS
0.497x
Automobile &Pc
KO:015260
0.067x
Iltani Resources Ltd
AU:ILT
-0.009x
Unifosa
TWO:8277
0.002x
Four Seasons Education Cayman
NYSE:FEDU
N/A
Alumexx N.V.
AS:ALX
0.571x

Annual Cash Flow Conversion Efficiency for Lyka Labs Limited (2005–2025)

The table below shows the annual cash flow conversion efficiency of Lyka Labs Limited from 2005 to 2025. For the full company profile with market capitalisation and key ratios, see Lyka Labs Limited market capitalisation.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-03-31 Rs1.04 Billion
≈ $11.20 Million
Rs18.99 Million
≈ $205.41K
0.018x -29.41%
2024-03-31 Rs682.65 Million
≈ $7.38 Million
Rs17.73 Million
≈ $191.78K
0.026x -86.75%
2023-03-31 Rs456.71 Million
≈ $4.94 Million
Rs89.53 Million
≈ $968.19K
0.196x -96.66%
2022-03-31 Rs134.91 Million
≈ $1.46 Million
Rs792.46 Million
≈ $8.57 Million
5.874x +1772.76%
2021-03-31 Rs-250.93 Million
≈ $-2.71 Million
Rs88.11 Million
≈ $952.93K
-0.351x +0.32%
2020-03-31 Rs-151.11 Million
≈ $-1.63 Million
Rs53.23 Million
≈ $575.71K
-0.352x -160.45%
2019-03-31 Rs457.59 Million
≈ $4.95 Million
Rs266.66 Million
≈ $2.88 Million
0.583x +211.82%
2018-03-31 Rs582.36 Million
≈ $6.30 Million
Rs108.83 Million
≈ $1.18 Million
0.187x -74.93%
2017-03-31 Rs421.01 Million
≈ $4.55 Million
Rs313.81 Million
≈ $3.39 Million
0.745x +1938.60%
2016-03-31 Rs491.54 Million
≈ $5.32 Million
Rs-19.93 Million
≈ $-215.50K
-0.041x -107.11%
2015-03-31 Rs465.71 Million
≈ $5.04 Million
Rs265.40 Million
≈ $2.87 Million
0.570x -64.17%
2014-03-31 Rs560.17 Million
≈ $6.06 Million
Rs890.99 Million
≈ $9.64 Million
1.591x +914.04%
2013-03-31 Rs697.62 Million
≈ $7.54 Million
Rs109.43 Million
≈ $1.18 Million
0.157x +154.43%
2012-03-31 Rs755.73 Million
≈ $8.17 Million
Rs-217.78 Million
≈ $-2.36 Million
-0.288x -380.89%
2010-03-31 Rs1.43 Billion
≈ $15.41 Million
Rs146.23 Million
≈ $1.58 Million
0.103x +129.68%
2008-03-31 Rs780.73 Million
≈ $8.44 Million
Rs-269.87 Million
≈ $-2.92 Million
-0.346x -33.00%
2007-03-31 Rs460.74 Million
≈ $4.98 Million
Rs-119.75 Million
≈ $-1.29 Million
-0.260x -136.00%
2005-03-31 Rs286.25 Million
≈ $3.10 Million
Rs206.68 Million
≈ $2.24 Million
0.722x --

About Lyka Labs Limited

NSE:LYKALABS India Biotechnology
Market Cap
$23.04 Million
Rs2.13 Billion INR
Market Cap Rank
#24584 Global
#1365 in India
Share Price
Rs59.70
Change (1 day)
-1.13%
52-Week Range
Rs44.95 - Rs123.63
All Time High
Rs254.30
About

Lyka Labs Limited, a pharmaceutical company, develops, manufactures, and markets pharmaceutical formulations and active pharmaceutical ingredients in India. The company manufactures and sells various formulations, including emollient, topical steroid, antifungal agent, topical anti-bacterial, acne management, dermatological formulation, pain killer, anti-aging, cleansing lotion, hair care, anti-d… Read more